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Abstract
Limited information is available on the efficacy of front-line bendamustine and 
rituximab (BR) in chronic lymphocytic leukemia (CLL) with reduced renal function 
or coexisting conditions. We therefore analyzed a cohort of real-world patients and 
performed a matched adjusted indirect comparison with a cohort of patients treated 
with ibrutinib. One hundred and fifty-seven patients with creatinine clearance (CrCl) 
<70  mL/min and/or CIRS score >6 were treated with BR. The median age was 
72 years; 69% of patients had ≥2 comorbidities and the median CrCl was 59.8 mL/
min. 17.6% of patients carried TP53 disruption. The median progression-free survival 
(PFS) was 45 months; TP53 disruption was associated with a shorter PFS (P = 0.05). 
The overall survival (OS) at 12, 24, and 36 months was 96.2%, 90.1%, and 79.5%, re-
spectively. TP53 disruption was associated with an increased risk of death (P = 0.01). 
Data on 162 patients ≥65 years treated with ibrutinib were analyzed and compared 
with 165 patients ≥65 years treated with BR. Factors predicting for a longer PFS at 
multivariable analysis in the total patient population treated with BR and ibrutinib 
were age (HR 1.06, 95% CI 1.02-1.10, P < 0.01) and treatment with ibrutinib (HR 
0.55, 95% CI 0.33-0.93, P = 0.03). In a post hoc analysis of patients in advanced 
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1 |  INTRODUCTION
With 20,720 estimated new cases and 3930 deaths in 2019 in 
the United States, chronic lymphocytic leukemia (CLL) is the 
most frequent leukemia in western countries.1 Because the me-
dian age at diagnosis is around 70 years and many patients carry 
one or more comorbidities, the most effective chemoimmuno-
therapy (CIT) regimen, fludarabine, cyclophosphamide, and 
rituximab (FCR), cannot be safely administered, thus making 
other options like a combination of the anti CD20 monoclonal 
antibody rituximab with bendamustine (BR) or chlorambucil2 
a widely employed therapeutic strategy in the clinical practice. 
The efficacy and safety of these combinations in the front-line 
setting have been documented in phase-2 and phase-3 trials 
including fit patients randomized to either FCR or BR,3-5 or 
patients deemed ineligible for fludarabine due to coexisting 
conditions and/or reduced renal function who were treated with 
chlorambucil and anti CD20 monoclonal antibodies.6-10 The 
BR combination was also tested in a limited number of patients 
not deemed fit to receive fludarabine-based regimens at physi-
cian's discretion9 and in older patients with preserved or moder-
ately impaired renal function.11
In recent years, evidence has been provided that a longer 
progression-free survival (PFS) can be achieved with ibruti-
nib than with CIT in previously untreated CLL10-12 and ex-
pert opinions recommended ibrutinib upfront, especially in 
older patients with CLL and in younger patients with TP53 
disruption or less favorable unfavorable immunogenetic char-
acteristics, that is, unmutated configuration of the variable 
portion of the immunoglobulin (IGHV) gene.13-15
Interestingly, an observational study of CIT in the "re-
al-world" setting showed that these regimens may prove safe 
and effective,16-18 even though dose reductions may occur 
commonly in clinical practice and may impact on outcome.19 
Likewise, the rates of ibrutinib discontinuation and survival 
are likely to be worse in a real-world setting than in a clinical 
trial possibly due to inclusion of patients with poorer per-
formance status and more comorbidities.20-22 A matched-ad-
justed indirect comparison of patients who had received BR 
or ibrutinib as first salvage treatment outside of clinical trials 
showed no OS difference.17
Because limited information is available on the efficacy 
and safety of BR in unfit patients, we analyzed the efficacy 
of this regimen in a cohort treated outside clinical trials 
and we carried out an indirect comparison with a cohort of 
older patients treated with ibrutinib front-line in a real-world 
setting.23
2 |  METHODS
2.1 | Patients
The patients included in this report were retrospectively se-
lected as outlined below from a cohort of patients treated 
front-line with BR between 2008 and 2014 at GIMEMA and 
European Research Initiative on CLL (ERIC) centers and 
from a cohort of CLL patients treated front-line with ibrutinib 
at 20 community and academic US centers.16,22
2.2 | BR regimen in unfit CLL
Inclusion criteria in this analysis were (a) CLL progres-
sion according to the NCI criteria24 (b) no previous treat-
ment for CLL, (c) creatinine clearance <70 mL/min and/
or CIRS > 6, that is unfit patients as previously defined,6 
(d) and received at least 1  day of treatment with the BR 
regimen.25 Patients were excluded from the study if they 
had transformation of CLL into Richter's syndrome be-
fore starting treatment, known HIV infection, active and 
uncontrolled HCV and/or HBV infections. Treatment re-
sponse and disease progression were assessed according 
to the NCI criteria.24 The primary endpoint was 12-month 
progression-free survival (PFS). Secondary endpoints were 
overall response rate (ORR), time to next anti-leukemic 
treatment (TTNT), and overall survival (OS) as previously 
defined.17 Safety data were reported according to the NCI 
Common Terminology Criteria for Adverse Events ver-
sion 4.0. The study was registered at ClinicalTrials.gov 
(NCT02491398). The study was approved by the institu-
tional review board of each participating institution.
stage, a significant PFS advantage was observed in patient who had received ibruti-
nib (P = 0.03), who showed a trend for OS advantage (P = 0.08). We arrived at the 
following conclusions: (a) BR is a relatively effective first-line regimen in a real-
world population of unfit patients without TP53 disruption, (b) ibrutinib provided 
longer disease control than BR in patients with advanced disease stage.
K E Y W O R D S
bendamustine, chronic lymphocytic leukemia, ibrutinib, real-world analysis, unfit patients
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2.3 | Indirect comparison with ibrutinib
For the purpose of this analysis, we retrieved pertinent data by 
reviewing clinical charts, electronic medical records, and re-
lated databases in patients ≥65 years enrolled in the GIMEMA 
ERIC study who had received BR in first line and in patients 
≥65 years of a US study who had received single agent ibruti-
nib.22 The patients with del(17p) or TP53 mutations were ex-
cluded. The endpoints for this analysis were the PFS and OS.
2.4 | Statistical analysis
The analyses were performed following the intention-to-treat 
principle as previously described.17 All analyses were performed 
using the SAS software (version 9.4 or later); all tests were two-
sided, at a significance level of 0.05. Study data were collected 
and managed using REDCap electronic data capture tools.26 The 
data that support the findings of this study are available from the 
corresponding author upon reasonable request.
3 |  RESULTS
3.1 | Treatment with BR in unfit patients
One hundred fifty-seven patients treated at 31 centers (24 
GIMEMA centers and 7 ERIC centers) were included. The de-
mographic data at baseline have been outlined in Table 1. The 
median age was 72 years; 80.9% of patients was >65 years; 
69.2% had 2 or more comorbidities, the median creatinine 
clearance was 59,8 mL/min and 58.9% had Binet stage B-C. 
Fifty-one percent (data available in 56.7% of the patients) had 
an unmutated IGHV gene configuration, 17.6% carried 17p- 
and/or TP53 mutation (data available in 83.4% of the patients).
One hundred and fourteen of 157 patients (73.1%) received 
the planned number of cycles; treatment was discontinued as a 
result of toxicity in 18% patients (n = 28), withdrawal of consent 
in 2% (n = 3), or other reasons in 7% (n = 11). The number of 
cycles actually administered to patients who discontinued treat-
ment was ≥4 in 71% of cases. The starting dose of bendamustine 
was 90 mg/m2 in 45.8% of the patients, 70 mg/m2 in 33.1% of the 
patients and 50-70 mg/m2 in 21.1% of the patients. A dose reduc-
tion >10% of the planned dose of bendamustine was recorded in 
24.2% of cases; treatment delay occurred in 22.9% of patients.
Second-line treatment was offered at symptomatic pro-
gression according to local guidelines.
3.2 | Efficacy
The ORR to BR was 91.7%. The probability of attaining a re-
sponse was significantly lower in patients with del(17p)/TP53 
mutations as compared to patients without del(17p)/TP53 
mutations (50% vs 85.1%, P = 0.02). Other variables had no 
significant impact on the ORR (Table S2).
The median PFS was 45 months (Figure 1(A)), with a 
12-month PFS rate of 93% (95% CI 89.0%-97.1%). The 
estimated PFS at 24 and at 36  months were 81% (95% 
CI 74.5%-88.2%) and 66.8% (95% CI 74.5%-88.2%), 
respectively. Factors associated with a shorter PFS in 
univariate analysis were represented by del(17p)/TP53 
mutations, ECOG performance status and by the pres-
ence of 2 or more comorbidities, as shown in Table  2, 
whereas an intermediate/advanced stage and an IGHV-
unmutated status were of borderline significance. Age 
(cut-off 65  years) and other clinicobiologic parameters 
had no impact on PFS. del(17p)/TP53 mutations repre-
sented the only adverse parameter in multivariable anal-
ysis (Table 2, Figure 1(B)).
A second-line treatment was administered to 3.2% (95% 
CI 1.2%-6.9%), 8.3% (95% CI 4.3%-13.9%), and 21.5% (95% 
CI 13.1%-31.1%) of patients at 12, 24, and 36 months, re-
spectively (Figure S1). A shorter TTNT was associated with 
del(17p)/TP53 mutation (P < 0.01; Table S2).
The OS at 12, 24, and 36 months were 96.2% (95% CI 
93.2%-99.2%), 90.1% (95% CI 85.0%-95.5%), and 79.5% 
(95% CI 70.0%-90.5%), respectively, with a median OS 
that was not reached with a 26-month median follow-up 
(Figure  2). The presence of del(17p)/TP53 mutation 
(P  <  0.01) and lack of response to treatment (P  <  0.01) 
were associated with a shorter OS in univariate as well as 
T A B L E  1  Baseline characteristics of 157 patients in the 
bendamustine and rituximab (BR) cohort
Variable (n. of patients) N. of patients (%)
age ≤ 65/>65 years (n = 157) 30 (19.1)/127 (80.9)




gender male/female (n = 157) 95 (60.5)/62 (39.5)
ECOG PS 0/1/ ≥2 (n = 154) 68 (43.3)/70 (44.6)/ 16 
(10.2)
N. of comorbidities 0-1/≥ 2 (n = 156) 48 (30.8)/108 (69.2)
Median Cr Cl ml/min (range) (n = 157) 59.8 (22.0−137.0)
beta 2 microglobulin ≥ 3.5/<3.5 mg/L 
(n = 113)
94 (83.2)/19 (16.8)
IGHV Mutated/Unmutated (n = 89) 44 (49.4)/45 (50.6)
17p- and/or TP53 mutated yes/no 
(n = 131)
23 (17.6)/108 (82.4)
FISH abns 13q-/+12/11q-/17p-/normal 
(n = 111)
34 (30.6)/24 (21.6)/10 
(9.0)/7 (6.3)/36 (32.4)
Note: Legend: ECOG PS, Eastern Cooperative Oncology Group Performance 
Status; Cr Cl, Creatinine clearance.
aEarly: Binet A. 
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in multivariate analysis (Table 3). Other clinicobiologic pa-
rameters had no impact on OS. Twenty-two patients died 
(n = 2 due to CLL, 9.1%; n = 12 infection with or without 
active CLL, 54.6%; n = 3 second primary tumors, 13.6%; 
1 each cardiac disease and sudden death). In three patients, 
the cause of death was not reported.
3.3 | Safety
Forty-two percent of the BR patients reported at least one 
grade 3-4 adverse event. Overall, cytopenias were recorded 
in 34% of patients. Grade 3-4 neutropenia occurred in 24% 
of cases. Grade 3-4 infections including febrile neutropenia 
were recorded in 11% of patients. One case of fatal infection 
was reported. Grade 3-4 rash and/or dermatitis were reported 
3% of patients.
3.4 | Comparison of BR in the GIMEMA-
ERIC dataset and ibrutinib in the US dataset
Data on 165 and 162 older patients without del(17p)/TP53 
aberrations treated with BR and ibrutinib, respectively, 
were analyzed. The median follow-up in the BR and in 
the ibrutinib cohorts was 29 months (95% CI 26-31) and 
13  months (95% CI 10-14), respectively. As shown in 
Table 4, the two cohorts were comparable in terms of age 
and frequency of del(11q). Patients with advanced Rai 
stage were more frequently represented in the ibrutinib 
cohort than in the BR cohort, and the interval between 
diagnosis and treatment was significantly longer in the 
ibrutinib cohort.
Factors associated with a longer PFS in multivariate 
analysis in the combined patient population treated with 
BR and ibrutinib were represented by age as a continuous 
F I G U R E  1  PFS in 157 patients treated with BR (A) in the entire cohort, (B) in patients with and without 17p-/TP53 mutation
Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Age > 65 vs ≤ 65 years 1.85 (0.66-5.24) 0.24
Binet B-C vs Binet A 2.16 (0.95-4.92) 0.07
beta 2 microglobulin ≥ 3.5 
vs < 3.5 mg/L
1.64 (0.57-4.70) 0.36
IGHV unmutated vs 
mutated
2.29 (0.92-5.69) 0.07
17p- and/or TP53 mutated 
yes vs no
3.14 (1.29-7.63) 0.01 2.52 (1.00-6.39) 0.05
Gender female vs male 0.60 (0.31-1.17) 0.13
ECOG 0 vs 1 1.64 (0.78-3.46) 0.19
ECOG 0 vs ≥ 2 3.12 (1.25-7.81) 0.02




T A B L E  2  Progression-free survival 
(PFS): univariate and multivariate analyses 
in the bendamustine and rituximab (BR) 
cohort
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variable and by treatment with ibrutinib (Table  5). Age 
was the only factor predicting for shorter OS at multivari-
able analysis (HR 1.10, 95% CI 1.04 - 1.15, P < 0.01).
In a post hoc analysis including patients in advanced 
stage (ie Rai III-IV), the ibrutinib cohort (n = 96 patients), 
and the BR cohort (n  =  46 patients) were comparable in 
terms of age (cut-off 70 years) and interval between diag-
nosis and first-line treatment (cut-off 36 months), as shown 
in Table 6. A significant PFS advantage was observed in the 
ibrutinib cohort (P = 0.03), which also showed a trend for an 
advantage in terms of OS (P = 0.08, Figure 3(A) and (B)). 
Patients in early/intermediate stage in the BR (n = 79) and 
in the ibrutinib cohort (n = 59) had similar age and similar 
interval between diagnosis and first-line treatment charac-
teristics (Table 6). No difference was noted in terms of PFS 
(P = 0.89) and OS (P = 0.66) in these patients (Figure 4(A) 
and (B)).
4 |  DISCUSSION
This is the first robust report of the efficacy and safety of BR 
in unfit patients treated outside clinical trials, as these patients 
were usually enrolled in trials using chlorambucil and an anti 
CD20 monoclonal antibody.6,27 Even though chlorambucil is 
the preferred option as chemotherapy backbone in this subset 
F I G U R E  2  OS in 157 patients treated with BR (A) in the entire cohort, (B) in patients with and without 17p-/TP53 mutation, (C) in patients 
who had a response to treatment vs patients who did not respond to treatment
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Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Age > 65 vs ≤ 65 years 3.95 (0.53-29.50) 0.18




IGHV unmutated vs 
mutated
0.81 (0.22-3.05) 0.76
17p- and/or TP53 
mutated yes vs no
6.14 (2.08-18.13) <0.01 4.47 (1.37-14.56) 0.01
NR vs CR or PR 8.43 (3.52-20.19) <0.01 15.21 (5.72-40.74) <0.01
Gender female vs male 0.68 (0.29-1.64) 0.39
ECOG 0 vs 1 2.28 (0.79-6.59) 0.13
ECOG 0 vs ≥ 2 4.90 (1.48-16.19) 0.01





no-aberrations vs 13q 0.74 (0.12-4.45) 0.74
11q- vs 13q 3.18 (0.52-19.37) 0.21
+12 vs 13q 3.88 (0.90-16.71) 0.07
17p- vs 13q 11.29 (2.08-61.14) <0.01
Legend: NR, no response; CR, complete response; PR, partial response.
T A B L E  3  Overall survival (OS): 
univariate and multivariate analyses in the 
bendamustine and rituximab (BR) cohort
BR n = 165 (%) ibrutinib = 162 (%) P
Age ≤ 70/ >70 years 53 (32.1)/ 112 (67.9) 53 (32.7)/ 109 (67.3) 1.00
gender Male/ Female 106 (64.2)/ 59 (35.8) 102 (63.0)/ 60 (37.0) 0.90
Time dx-trxa  < 36/≥36 months 99 (60.0)/ 66 (40.0) 69 (42.6)/ 93 (57.4) <0.01
RAIb stage 0-2/ 3-4 79 (63.2)/ 46 (36.8) 59 (38.1)/ 96 (61.9) <0.01
del11q no/ yes 101 (89.4)/ 12 (10.6) 125 (87.4)/ 18 (12.6) 0.77
aInterval between diagnosis and treatment. 
bThe Rai staging system was used here because it was adopted in the US cohort. 
T A B L E  4  Baseline characteristics of 






PHR (95% CI) HR (95% CI)
Age (as continuous 
variable)
1.05 (1.02-1.09) <0.01 1.06 (1.02-1.10) <0.01
RAI 3-4 vs 0-2 1.09 (0.66-1.79) 0.73 — —
11q- yes vs no 2.13 (1.04-4.37) 0.04 — —
Time dx-trxa 
(continuous variable)
1.00 (0.99-1.00) 0.62 — —
interval dx-trxa  ≥ 36 
vs < 36 months
0.89 (0.57-1.38) 0.61 — —
Ibr vs. BR 0.60 (0.36-1.01) 0.05 0.55 (0.33-0.93) 0.03
aInterval between diagnosis and treatment 
T A B L E  5  Univariate and 
multivariable analysis of PFS in the 
total patient population treated with 
bendamustine and rituximab (BR) and 
ibrutinib
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of CLL,15 BR is a widely adopted front-line regimen in the 
clinical practice for elderly CLL patients with coexisting 
conditions.28,29
Even though this study is not based on a registry reporting 
the efficacy of BR and ibrutinib in all the incident CLL cases and 
accepting the limitations of a retrospective analysis, to ensure 
T A B L E  6  Baseline characteristics in patients with advanced (Rai III-IV) and early/intermediate stage (Rai 0-II) in the bendamustine and 
rituximab (BR) and ibrutinib cohorts










Age ≤70 years 16 (34.8) 27 (28.1) 0.54 31 (39.2) 22 (37.3) 0.96
>70 years 30 (65.2) 69 (71.9) 48 (60.8) 37 (67.2)
Gender Male 31 (67.4) 58 (60.4) 0.54 49 (62.0) 38 (64.4) 0.91
Female 15 (32.6) 38 (39.6) 30 (38.0) 21 (35.6)
Time dx-trxa <36 months 25 (54.3) 35 (36.5) 0.07 50 (63.3) 30 (50.8) 0.20
≥36 months 21 (45.7) 61 (63.5) 29 (36.7) 29 (49.2)
del11q No 26 (78.8) 77 (88.5) 0.29 55 (96.5) 41 (83.7) 0.06
Yes 7 (21.2) 10 (11.5) 2 (3.5) 8 (16.3)
aTime dx-trx: Interval between diagnosis and treatment. 
F I G U R E  3  PFS (A) and OS (B) in the BR and in the ibrutinib cohort in (Rai stage III-IV)
F I G U R E  4  PFS (A) and OS (B) in the BR and in the ibrutinib cohort in (Rai stage 0-II)
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accuracy in data collection we encouraged each participating 
center to include all patients who started BR and we performed 
consistency checks on each case report form. Furthermore, we 
included, in addition to PFS, objective measures of efficacy 
such as OS and TTNT. Because bone biopsy was not manda-
tory, we were not able to assess complete response.
Our BR cohort resembled closely patients with CLL 
treated in the daily clinical practice in terms of age, cre-
atinine clearance, performance status and comorbidities.30 
The percentage of patients with early stage disease in our 
analysis (41.1%) was higher than in GCLLSG and in UK 
trials, where 23% and 33% of the patients, were in Binet 
stage A, respectively.6,31 This finding reflects the tendency 
to initiate treatment in the presence of a short lymphocyte 
doubling time or of symptomatic disease in this unfit pa-
tient population.
The proportion of patients who completed the planned 
therapy in our analysis (73.1%) is in line with the data form 
the MABLE trial that compared chlorambucil and ritux-
imab with the BR regimen in a fludarabine-ineligible CLL 
population.9
Grade 3-4 infections in this study (11%) occurred at a 
similar frequency as in clinical trials (7.7%-19%).9,11,25 We 
observed a lower incidence of grade 3-4 cytopenia (34%) 
compared to other studies reporting a 52.1%-56% incidence 
of cytopenia due to fact that many investigators did not per-
form a blood count at the nadir time point.
With a median PFS of 45.1 months and a projected OS 
rate at 24 and 36 months of 90.1% and 79.5%, respectively, 
our data show that BR is an effective front-line treatment op-
tion for an unfit patient population treated outside of clini-
cal trials. The only baseline characteristics with a significant 
negative impact on the efficacy endpoints in this study were 
represented by the TP53 disruption and, interestingly, failure 
to respond to BR was an independent dynamic prognostic 
factor for OS, a finding probably reflecting the lack of effec-
tive salvage treatment for a proportion of patients during the 
study period. The IGHV-unmutated configuration was asso-
ciated with a shorter PFS, that was of borderline significant 
probably as a consequence of the limited number of patients 
assessed.
In our analysis PFS is similar to that observed in the 
MABLE trial (median 39.6 months).9 Interestingly, a median 
PFS of 33.9 months was observed in the subset of patients 
with creatinine clearance <70 in a phase-2 study25 and a me-
dian PFS of 43 months with a 74% PFS rate at 24 months was 
reported in a trial enrolling older CLL patients.11 Notably, 
OS was similar in our analysis and in prospective trials which 
reported an OS rate of approximately 80% at 36 months and 
an OS rate of 90%-95% at 24 months.11,25
It is worth noting that chlorambucil and rituximab pro-
duced an 87% ORR with an OS rate at 48 and 60 months of 
86.1% (95% CI: 79.4-93.5) and 81.2% (95% CI: 72.4-91.2), 
respectively, in elderly patients treated outside clinical tri-
als.18 Likewise, an 80.3% ORR and estimated 2-year OS of 
88% was recorded by the Israeli end ERIC group in elderly 
patients who received chlorambucil and obinutuzumab, with-
out unexpected adverse events.32 Taken together, these data 
show that the efficacy and safety of different CIT regimens 
in routine clinical practice are consistent with those reported 
in clinical trials.
Because there is evidence that treatment continuation and 
efficacy with ibrutinib may be inferior outside of clinical 
trials,21,22 and given the growing importance of real world 
evidence which can provide invaluable information to sup-
plement randomized clinical studies,33 we elected to compare 
PFS and OS in a cohort treated with ibrutinib in a real-world 
experience in the USA23 with a similar patient population 
treated with BR at the GIMEMA-ERIC centers.
Although the two groups were treated in different time pe-
riods with consequent difference in follow-up time, we per-
formed an indirect comparison trying to minimize the effect 
of the heterogeneity of patient populations.
First, we documented that in the total study population 
(excluding patients with 17p-) age and treatment with ibru-
tinib were associated with a longer PFS in multivariate 
analysis.
When restricting our analysis to patients with advanced 
stage (Rai III-IV) with comparable baseline characteristics, 
we were able to show that ibrutinib was associated with a 
longer PFS and a trend of longer OS as compared with BR, 
whereas no difference was observed in patients with early in-
termediate stage. Though caution should be exercised when 
interpreting these data, as they were obtained in quite a small 
number of patients treated outside of clinical trial, it is note-
worthy that similar findings were reported in a randomized 
prospective study.34
Taken together our data show that (a) BR is a safe and 
effective first-line regimen in a real-world cohort of unfit 
CLL patients, with the exception of patients with unfavor-
able genetic characteristics (ie del(17p)/TP53 aberrations and 
IGHV-unmutated configuration, (b) there are no appreciable 
differences in terms of efficacy and safety between BR in 
clinical trials that enrolled older patients with CLL and this 
real world experience on unfit patients with reduced renal 
function and with coexisting conditions and, (ci) and ibru-
tinib provided more durable disease control than BR in the 
front-line setting in patients treated outside of clinical trials, 
especially in patients with advanced disease stage.
While providing evidence that BR is an effective first-line 
regimen in unfit patients, these data reinforce the notion that 
ibrutinib has an established place in the front-line treatment 
of older patients with CLL.11,15,35 These findings may have 
practical implications in the definition of treatment algo-
rithms, especially in those countries with restrictions to the 
use of ibrutinib or other oral agents.36,37
10 |   CUNEO Et al.
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